AtriCure, Inc. provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery. It also provides SUBTLE cannula, an access device and conduit for the ablation device and endoscope to enable a closed chest endoscopic approach; multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable physicians to create an expanded cardiac ablation lesion set. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. AtriCure sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:ATRC
CUSIP04963C20
Phone513-755-4100
Debt
Debt-to-Equity Ratio0.34
Current Ratio3.15
Quick Ratio2.31
Price-To-Earnings
Trailing P/E Ratio-33.43
Forward P/E Ratio-32.27
P/E GrowthN/A
Sales & Book Value
Annual Sales$174.72 million
Price / Sales5.57
Cash FlowN/A
Price / CashN/A
Book Value$4.67 per share
Price / Book5.94
Profitability
EPS (Most Recent Fiscal Year)($0.83)
Net Income$-26,890,000.00
Net Margins-14.88%
Return on Equity-16.92%
Return on Assets-9.99%
Miscellaneous
Employees570
Outstanding Shares35,040,000
AtriCure (NASDAQ:ATRC) Frequently Asked Questions
What is AtriCure's stock symbol?
AtriCure trades on the NASDAQ under the ticker symbol "ATRC."
How were AtriCure's earnings last quarter?
AtriCure Inc. (NASDAQ:ATRC) announced its quarterly earnings results on Thursday, April, 26th. The medical device company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.27) by $0.04. The medical device company earned $46.99 million during the quarter, compared to the consensus estimate of $45.43 million. AtriCure had a negative return on equity of 16.92% and a negative net margin of 14.88%. The company's revenue for the quarter was up 13.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.32) EPS. View AtriCure's Earnings History.
When is AtriCure's next earnings date?
What price target have analysts set for ATRC?
4 brokers have issued 12-month price targets for AtriCure's stock. Their forecasts range from $23.00 to $32.00. On average, they expect AtriCure's share price to reach $26.25 in the next year. View Analyst Ratings for AtriCure.
What are Wall Street analysts saying about AtriCure stock?
Here are some recent quotes from research analysts about AtriCure stock:
- 1. Needham & Company LLC analysts commented, "We have increased confidence in ATRC’s ability to sustain strong revenue growth and to drive upside to consensus estimates given: 1) strong Open-Heart Ablation growth driven by society guidelines and increasing penetration, 2) strong AtriClip growth driven by new products with higher prices, 3) conservative guidance, and 4) easing comps, particularly in 2H18. Additionally, we expect ATRC’s analyst meeting (6/26 in NYC) to serve as a nearer-term catalyst and results from its CONVERGE trial to serve a a significant longer-term catalyst in 2H19. Given this, we raise our price target to $32 from $26 and reiterate our Buy rating." (6/18/2018)
- 2. According to Zacks Investment Research, "AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart. " (5/2/2018)
Who are some of AtriCure's key competitors?
Some companies that are related to AtriCure include NuVasive (NUVA), Novocure (NVCR), Merit Medical Systems (MMSI), Nevro (NVRO), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Glaukos (GKOS), Luminex (LMNX), Orthofix International (OFIX), Atrion (ATRI), Intersect ENT (XENT), Cardiovascular Systems (CSII), OraSure Technologies (OSUR), Tandem Diabetes Care (TNDM) and Cryolife (CRY).
Who are AtriCure's key executives?
AtriCure's management team includes the folowing people:
- Mr. Michael H. Carrel, CEO, Pres & Director (Age 47)
- Mr. M. Andrew Wade CPA, Sr. VP & CFO (Age 43)
- Mr. Douglas J. Seith, Chief Operating Officer (Age 52)
- Mr. Salvatore Privitera, Chief Technology Officer (Age 51)
- Mr. Justin J. Noznesky, Sr. VP of Marketing & Bus. Devel. (Age 40)
Has AtriCure been receiving favorable news coverage?
Headlines about ATRC stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. AtriCure earned a news impact score of 0.03 on Accern's scale. They also gave press coverage about the medical device company an impact score of 44.15 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are AtriCure's major shareholders?
AtriCure's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.48%), Hudson Executive Capital LP (6.78%), First Light Asset Management LLC (3.33%), Millennium Management LLC (2.45%), Loomis Sayles & Co. L P (2.30%) and Neuberger Berman Group LLC (2.23%). Company insiders that own AtriCure stock include Andrew L Lux, B Kristine Johnson, Elizabeth D Krell, Justin J Noznesky, M Andrew Wade, Mark A Collar and Regina E Groves. View Institutional Ownership Trends for AtriCure.
Which institutional investors are selling AtriCure stock?
ATRC stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, BlackRock Inc., GSA Capital Partners LLP, Neuberger Berman Group LLC, Wasatch Advisors Inc., Loomis Sayles & Co. L P, Nuveen Asset Management LLC and A.R.T. Advisors LLC. Company insiders that have sold AtriCure company stock in the last year include Elizabeth D Krell, Justin J Noznesky, M Andrew Wade and Mark A Collar. View Insider Buying and Selling for AtriCure.
Which institutional investors are buying AtriCure stock?
ATRC stock was purchased by a variety of institutional investors in the last quarter, including Hudson Executive Capital LP, The Manufacturers Life Insurance Company , Millennium Management LLC, First Light Asset Management LLC, Quantum Capital Management, Tamarack Advisers LP, Trexquant Investment LP and Highbridge Capital Management LLC. Company insiders that have bought AtriCure stock in the last two years include B Kristine Johnson and Regina E Groves. View Insider Buying and Selling for AtriCure.
How do I buy shares of AtriCure?
Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AtriCure's stock price today?
One share of ATRC stock can currently be purchased for approximately $27.75.
How big of a company is AtriCure?
AtriCure has a market capitalization of $979.02 million and generates $174.72 million in revenue each year. The medical device company earns $-26,890,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. AtriCure employs 570 workers across the globe.
How can I contact AtriCure?
AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100.
MarketBeat Community Rating for AtriCure (ATRC)
MarketBeat's community ratings are surveys of what our community members think about AtriCure and other stocks. Vote "Outperform" if you believe ATRC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRC will underperform the S&P 500 over the long term. You may vote once every thirty days.
